EDMONTON, Alberta, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a
growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and
cosmetic industries, today announced the granting of stock options (“options”) and restricted share units (“RSUs”) to all
employees, officers and directors of the Company.
Options to purchase 420,000 common shares were granted pursuant to the Company’s Stock Option Plan, with an
exercise price of $0.38.5 per common share. Each grant vests in three equal instalments, the first of which vests immediately with
the second and third instalments vesting on the first and second anniversaries of the date of grant. Each option is exercisable,
once vested, for a period of five years from the date of the grant.
The Company also granted 280,000 RSUs pursuant to the Company’s Restricted Share Unit Plan. The RSU awards vest
in two equal instalments, the first of which vests on July 1, 2019 and the second on January 1, 2020. Each RSU entitles the holder
to receive one common share of the Company.
The granting of all options and RSUs is subject to TSX Venture approval.
In conjunction to these grants and to bolster success, the Company also confirmed strategic appointments to the
management team including the promotion of Mrs. Leoni DeJoya as Vice President, Bioprocessing Business Unit and the extension of an
agreement with Mr. Denis Bilodeau as Strategic Advisor to the Company.
Mrs. DeJoya, a certified engineer with over 25 years of experience in international manufacturing and QA/AC
joined Ceapro in 2008. As Vice President of Ceapro’s newly formed Bioprocessing Business Unit integrating the Company’s
manufacturing sites, she will be responsible for both technical operations and account management.
Mr. Denis Bilodeau, an established clinical, pharmaceutical and medical device expert with 35 years of
experience in the public and private sectors will work closely with the CEO for corporate development and Special Projects.
Please click here to access the full biographies of Ceapro’s management team.
About Ceapro Inc.
Ceapro Inc. is a Canadian biotechnology company involved in the development of proprietary extraction technology
and the application of this technology to the production of extracts and “active ingredients” from oats and other renewable plant
resources. Ceapro adds further value to its extracts by supporting their use in cosmeceutical, nutraceutical, and therapeutics
products for humans and animals. The Company has a broad range of expertise in natural product chemistry, microbiology,
biochemistry, immunology and process engineering. These skills merge in the fields of active ingredients, biopharmaceuticals and
drug-delivery solutions.
For more information on Ceapro, please visit the Company’s website at www.ceapro.com.
For more information contact:
Jenene Thomas
Jenene Thomas Communications, LLC
Investor Relations and Corporate Communications Advisor
T (US): +1 (833) 475-8247
E: czo@itcir.com
Issuer:
Gilles R. Gagnon, M.Sc., MBA
President & CEO
T: 780-421-4555
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of
the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
